Business
Publication of Annual Report
Publication of Annual Report.
About this update from Proteome Sciences Plc
[{"type":"text","content":"\n \nRNS Number : 7747Z Proteome Sciences PLC 31 May 2016 \n\n \n \n \n \nPRESS RELEASE\nProteome Sciences plc\n(the \"Company\" or the \"Group\")\n \nPublication of Annual Report\n \n31 May, 2016: The Company announces that its Annual Report and Accounts for the year ended 31 December 2015, together with a notice of the Annual General Meeting and accompanying form of proxy, are available to view on the Company's website at www.proteomics.com, and will be posted to shareholders imminently.\n \nENDS\n \nFor further information please contact:\n \n\n\n\n\nProteome Sciences plc\n\n\n\n\n\n\n\nChristopher Pearce, Executive Chairman\n\n\n\n\n\n\n\nDr. Ian Pike, Chief Operating Officer\n\n\nTel: +44 (0)1932 865065\n\n\n\n\nGeoff Ellis, Finance Director\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nfinnCap Limited (Nominated Adviser/Broker)\nGeoff Nash/James Thompson\n\n\n \nTel : +44 (0)20 7220 0563\n\n\n\n\n\n\n\n\n\n\n\n\nPublic Relations\n\n\n\n\n\n\n\nIKON Associates \n\n\nEmail: [email protected]\n\n\n\n\nAdrian Shaw \n\n\nTel: +44 (0)1483 271291\n\n\n\n\n\n\n\nMobile +44(0)7979 900733\n\n\n\n\n\n\n\n\n\n\n\n\n \n \n \n \n \nNotes for editors: \n \nAbout Proteome Sciences plc (www.proteomics.com)\nWith its HQ in Cobham, UK and laboratory facilities in London and Frankfurt, Proteome Sciences is a global leader in applied proteomics offering high sensitivity, proprietary technologies and workflows in cell signalling pathways (SysQuant®, TMTcalibrator™) and in protein biomarker discovery, validation and assay development.\nPS Biomarker Services® provides proteomics outsourcing services and proprietary biomarker assays from its ISO 9001: 2008 facility in Frankfurt, Germany to pharmaceutical, biotechnology, diagnostics companies and academia.\nProteome Sciences' research has discovered a large number of novel protein biomarkers in key human diseases with a focus mainly in neurological/neurodegenerative conditions and in cancer. It has patented blood biomarkers in Alzheimer's disease, stroke, brain damage and cancers for diagnostic and treatment applications that are available for licenses.\n \n \n \n \n\nThis information is provided by RNSThe company news service from the London Stock Exchange END ACSZFLFXQEFF...